Watch ONC. Know when insiders buy.
One email the day a filing lands. Free.
ONC
BeOne Medicines Ltd.
370.17
+1.11 +0.30%
USD · Oct 19, 07:40 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
25
FLAG · insiders 25, shorts 24
Insiders, 90 days
−$36.1M
net selling · 0 buys, 26 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $547.2BP/E 860.9DIV YIELD —FCF YIELD 0.24%REV TTM $6.1B +34.3%NET INCOME $655.7MNET CASH $4.3B52W 260.27 – 386.46NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.7B | +29.6% | 89.8% | $325M | $237M | +151.3% | 0.16 | $462.8M | $27.5M | $435.3M | Aug 5 |
| Q1 2026 · Mar 31 | $1.5B | +35.5% | 89.0% | $249.9M | $227.4M | +17802.1% | 0.15 | $201.3M | $40.8M | $160.5M | Aug 5 |
| Q4 2025 · Dec 31derived | $1.5B | +32.8% | 90.5% | $185M | $66.5M | — | 0.04 | $417.3M | $37.5M | $379.8M | Feb 26 |
| Q3 2025 · Sep 30 | $1.4B | +41.0% | 86.1% | $163.1M | $124.8M | — | 0.08 | $402.6M | $48.1M | $354.5M | Nov 6 |
| Q2 2025 · Jun 30 | $1.3B | +41.6% | 87.5% | $87.9M | $94.3M | — | 0.06 | $263.6M | $43.8M | $219.8M | Aug 5 |
| Q1 2025 · Mar 31 | $1.1B | +48.6% | 85.2% | $11.1M | $1.3M | — | 0.00 | $44.1M | $56.4M | −$12.3M | Aug 5 |
| Q4 2024 · Dec 31derived | $1.1B | +77.8% | 85.8% | −$79.4M | −$151.9M | — | -0.11 | $75.2M | $92.5M | −$17.3M | Feb 26 |
| Q3 2024 · Sep 30 | $1B | +28.2% | 83.0% | −$120.3M | −$121.3M | −156.3% | -0.09 | $188.4M | $133.7M | $54.7M | Nov 6 |
| Q2 2024 · Jun 30 | $929.2M | — | 85.1% | −$107.2M | −$120.4M | — | -0.09 | −$95.6M | $110M | −$205.5M | Nov 6 |
| Q1 2024 · Mar 31 | $751.7M | — | 83.4% | −$261.3M | −$251.2M | — | -0.19 | −$308.6M | $156.6M | −$465.1M | Nov 6 |
| Q4 2023 · Dec 31derived | $634.4M | — | 83.3% | −$383.8M | −$367.6M | — | -0.27 | −$221.6M | $157M | −$378.6M | Feb 26 |
| Q3 2023 · Sep 30 | $781.3M | — | 87.7% | −$134M | $215.4M | — | 0.15 | −$78.2M | $157.9M | −$236M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $5.3B | 87.5% | $447.1M | $286.9M | 5.4% | 0.19 | $1.1B | $185.8M | $941.7M | — | — |
| FY2024 · to Dec 31 | $3.8B | 84.4% | −$568.2M | −$644.8M | -16.9% | -0.47 | −$140.6M | $492.7M | −$633.3M | — | — |
| FY2023 · to Dec 31 | $2.5B | 84.5% | −$1.2B | −$881.7M | -35.9% | -0.65 | −$1.2B | $561.9M | −$1.7B | — | — |
| FY2022 · to Dec 31 | $1.4B | 79.8% | −$1.8B | −$2B | -141.5% | -1.49 | −$1.5B | $325.4M | −$1.8B | — | — |
| FY2021 · to Dec 31 | $1.2B | 86.0% | −$1.4B | −$1.5B | -123.9% | -1.21 | −$1.3B | $262.9M | −$1.6B | — | — |
| FY2020 · to Dec 31 | $308.9M | 77.1% | −$1.7B | −$1.6B | -526.1% | -1.50 | −$1.3B | $117.5M | −$1.4B | — | — |
Every number comes from BeOne Medicines Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.